• Tuberculosis and Respiratory Diseases
• /
• 제76권4호
• /
• pp.169-174
• /
• 2014

Background: The Korean Obstructive Lung Disease (KOLD) Cohort Study is a prospective longitudinal study of patients with chronic obstructive pulmonary disease (COPD), asthma, or other unclassified obstructive lung diseases. It was designed to develop new classification models and biomarkers that predict clinically relevant outcomes for patients with obstructive lung diseases. Methods: Patients over 18 years old who have chronic respiratory symptoms and airflow limitations or bronchial hyper-responsiveness were enrolled at 17 centers in South Korea. After a baseline visit, the subjects were followed up every 3 months for various assessments. Results: From June 2005 to October 2013, a total of 477 subjects (433 [91%] males; 381 [80%] diagnosed with COPD) were enrolled. Analyses of the KOLD Cohort Study identified distinct phenotypes in patients with COPD, and predictors of therapeutic responses and exacerbations as well as the factors related to pulmonary hypertension in COPD. In addition, several genotypes were associated with radiological phenotypes and therapeutic responses among Korean COPD patients. Conclusion: The KOLD Cohort Study is one of the leading long-term prospective longitudinal studies investigating heterogeneity of the COPD and is expected to provide new insights for pathogenesis and the long-term progression of COPD.

• Tuberculosis and Respiratory Diseases
• /
• 제77권4호
• /
• pp.155-160
• /
• 2014

Chronic obstructive pulmonary disease (COPD) is characterized by a diverse array of pulmonary and nonpulmonary manifestations, but our understanding of COPD pathogenesis and the factors that influence its heterogeneity in disease presentation is poor. Despite this heterogeneity, treatment algorithms are primarily driven by a single measurement, forced expiratory volume in 1 second ($FEV_1$) as a percentage of its predicted value ($FEV_1%$). In 2011, a major shift in Global Initiative for Chronic Obstructive Lung Disease (GOLD) treatment recommendations was proposed that stratifies patients with COPD on the basis of symptoms and exacerbation history. This article reviews the work reported in 2013 that enlightens our understanding of COPD with respect to COPD classification systems, phenotype, biomarker, exacerbation, and management for patients with COPD.

• Tuberculosis and Respiratory Diseases
• /
• 제78권1호
• /
• pp.8-17
• /
• 2015

Background: AMP-activated protein kinase (AMPK) not only functions as an intracellular energy sensor and regulator, but is also a general sensor of oxidative stress. Furthermore, there is recent evidence that it participates in limiting acute inflammatory reactions, apoptosis and cellular senescence. Thus, it may oppose the development of chronic obstructive pulmonary disease. Methods: To investigate the role of AMPK in cigarette smoke-induced lung inflammation and emphysema we first compared cigarette smoking and polyinosinic-polycytidylic acid [poly(I:C)]-induced lung inflammation and emphysema in $AMPK{\alpha}1$-deficient ($AMPK{\alpha}1$-HT) mice and wild-type mice of the same genetic background. We then investigated the role of AMPK in the induction of interleukin-8 (IL-8) by cigarette smoke extract (CSE) in A549 cells. Results: Cigarette smoking and poly(I:C)-induced lung inflammation and emphysema were elevated in $AMPK{\alpha}1$-HT compared to wild-type mice. CSE increased AMPK activation in a CSE concentration- and time-dependent manner. 5-Aminoimidazole-4-carboxamide-1-${\beta}$-4-ribofuranoside (AICAR), an AMPK activator, decreased CSE-induced IL-8 production while Compound C, an AMPK inhibitor, increased it, as did pretreatment with an $AMPK{\alpha}1$-specific small interfering RNA. Conclusion: $AMPK{\alpha}1$-deficient mice have increased susceptibility to lung inflammation and emphysema when exposed to cigarette smoke, and AMPK appears to reduce lung inflammation and emphysema by lowering IL-8 production.

• Tuberculosis and Respiratory Diseases
• /
• 제60권5호
• /
• pp.510-515
• /
• 2006

연구 배경 : 만성폐쇄성폐질환(COPD)은 45세 이상의 성인에서 국내 유병률 17.2%로 주요 질환이다. 하지만, 국내 COPD 환자의 사망원인에 대한 연구는 불충분한 상황이다. 이에 국내 COPD 환자 사망원인에 대해서 알아보고자 서울아산병원 의무기록을 후향적으로 조사하였다. 방 법 : 2003년 1년간 서울아산병원에서 COPD로 진료한 1,078명의 사망여부를 통계청에 의뢰하여 총 사망자 88명을 얻었고 이중 폐결핵 후유증, 기관지확장증, 폐암 등 암 환자를 제외한 후 남은 28명의 COPD 환자 대상으로 사망원인을 분석하였다. 결 과 : COPD 환자의 사망원인은 폐렴 등 호흡기 원인이 16명 (57%), 심장 원인 5명 (18%), 급사 3명 (11%), 기타 4명 (14%) 등이었다. 서울아산병원 내에서 사망한 환자와 외에서 사망한 환자의 호흡기 관련 사망이 각각 83%(10명/12명)과 38%(6명/16명)이었다 (P=0.05) $FEV_1$이 50%예측치보다 큰 환자와 작은 환자의 호흡기 관련 사망은 각각 43%과 55%이었다 (P=0.89). 결 론 : 국내 3차 병원에서 진료하는 COPD 환자의 사망 원인은 폐렴 등 호흡기 원인 다수를 차지한다.

• Tuberculosis and Respiratory Diseases
• /
• 제76권2호
• /
• pp.53-58
• /
• 2014

Chronic obstructive pulmonary disease (COPD) is a common airway disease that has considerable impact on disease burdens and mortality rates. A large number of articles on COPD are published within the last few years. Many aspects on COPD ranging from risk factors to management have continued to be fertile fields of investigation. This review summarizes 6 clinical articles with regards to the risk factors, phenotype, assessment, exacerbation, management and prognosis of patients with COPD which were being published last year in major medical journals.

• Tuberculosis and Respiratory Diseases
• /
• 제79권4호
• /
• pp.307-311
• /
• 2016

Pulmonary strongyloidiasis is an uncommon presentation of Strongyloides infection, usually seen in immunocompromised hosts. The manifestations are similar to that of acute exacerbation of chronic obstructive pulmonary disease (COPD). Therefore, the diagnosis of pulmonary strongyloidiasis could be challenging in a COPD patient, unless a high index of suspicion is maintained. Here, we present a case of Strongyloides hyperinfection in a COPD patient mimicking acute exacerbation, who was on chronic steroid therapy.

• Tuberculosis and Respiratory Diseases
• /
• 제61권2호
• /
• pp.129-136
• /
• 2006

연구 배경: 폐기능검사를 해석하는데 정상하한치(lower limits of normal) 선정과 해석흐름도 합의가 필수적이다. COPD 국제지침은 $FEV_1$/FVC 정상하한치로 0.7을 사용하여 폐쇄성장애를 진단한다. 한편, 미국흉부학회(ATS)와 유럽호흡기학회(ERS) 공동으로 새 해석흐름도를 제시하였다. '$FEV_1$/FVC 정상하한치 0.7' 의 정확성과 새 해석흐름도가 실제 폐기능검사 해석에 어떤 영향을 미치는지 알아 보고자 하였다. 방 법: 서울 아산병원의 호흡기검사실에서 2005년 7월 1일부터 11월 30일까지 5개월간 폐활량측정법을 시행한 7362명을 대상으로 하여 '$FEV_1$/FVC 정상하한치 0.7' 의 정확성을 평가하였고 새로운 ATS/ERS 해석흐름도에 따르면 폐용적검사가 추가로 필요한 경우가 얼마나 증가하는지 평가하였다. 상기 기간 내에 같은 날 폐용적검사를 시행한 1611 명을 대상으로 과거 해석흐름도와 비교하여 새로운 ATS/ERS 해석흐름도를 적용하게 되면 폐쇄성장애로 진단되는 경우가 얼마나 증가하는지 알아보았다. 결 과: 1) '$FEV_1$/FVC < 0.7' 에 의한 폐쇄성장애 진단은 연령이 증가할수록 민감도는 증가하였으나 특이도는 감소하였고 양성예측도는 감소하였으나 음성예측도는 증가하였다. 2) 새 ATS/ERS 해석흐름도를 적용할 경우 34.5% (2540명/7362명)의 환자가 추가로 폐용적검사가 필요하였다. 3) 새 ATS/ERS 해석흐름도를 적용할 경우, 과거에 제한성질환으로 진단되었던 환자 중 30%(205명/681명)가 폐쇄성질환으로 진단되었고 이는 전체 환자의 13%(205명/1611명)에 해당하였다. 결 론: 폐쇄성질환 진단기준으로 '$FEV_1$/FVC < 0.7' 을 사용하였을 때 연령에 따라서 민감도와 특이도가 변한다. 또한, 새로운 ATS/ERS 해석흐름도를 실제 환자를 진료하는데 적용하면 폐용적검사를 시행해야 하는 경우가 증가하게 되고 폐쇄성장애로 진단되는 경우가 더 증가하게 된다.

• Tuberculosis and Respiratory Diseases
• /
• 제79권4호
• /
• pp.207-213
• /
• 2016

Chronic obstructive pulmonary disease (COPD) encompasses several clinical syndromes, most notably emphysema and chronic bronchitis. Most of the current treatments fail to attenuate severity and progression of the disease, thereby requiring better mechanistic understandings of pathogenesis to develop disease-modifying therapeutics. A number of theories on COPD pathogenesis have been promulgated wherein an increase in protease burden from chronic inflammation, exaggerated production of reactive oxygen species and the resulting oxidant injury, or superfluous cell death responses caused by enhanced cellular injury/damage were proposed as the culprit. These hypotheses are not mutually exclusive and together likely represent the multifaceted biological processes involved in COPD pathogenesis. Recent studies demonstrate that mitochondria are involved in innate immune signaling that plays important roles in cigarette smoke-induced inflammasome activation, pulmonary inflammation and tissue remodeling responses. These responses are reviewed herein and synthesized into a view of COPD pathogenesis whereby mitochondria play a central role.

• Tuberculosis and Respiratory Diseases
• /
• 제83권4호
• /
• pp.257-267
• /
• 2020

Patients with chronic obstructive pulmonary disease receive a range of treatments including but not limited to inhaled bronchodilators, inhaled and systemic corticosteroids, supplemental oxygen, and pulmonary rehabilitation. Pulmonary rehabilitation is a multidisciplinary intervention that seeks to combine patient education, exercise, and lifestyle changes into a comprehensive program. Programs 6 to 8 weeks in length have been shown to improve health, reduce dyspnea, increase exercise capacity, improve psychological well-being, and reduce healthcare utilization and hospitalization. Although the use of pulmonary rehabilitation is widely supported by the literature, controversy still exists regarding what should be included in the programs. The goal of this review was to summarize the evidence for pulmonary rehabilitation and identify the areas that hold promise in improving its utilization and effectiveness.

• Tuberculosis and Respiratory Diseases
• /
• 제63권6호
• /
• pp.475-479
• /
• 2007